{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:55:37Z","timestamp":1768474537554,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.biologicals.2020.05.001","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T23:48:51Z","timestamp":1590104931000},"page":"30-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Potency evaluation of rabies vaccine for human use: The impact of reducing the number of animals per dilution \u2013 Part 2"],"prefix":"10.1016","volume":"66","author":[{"given":"Nathalia S.","family":"Machado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wildeberg C.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica F. de S.","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Eugenio C C de","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wlamir Correa de","family":"Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2020.05.001_bib1","doi-asserted-by":"crossref","first-page":"17091","DOI":"10.1038\/nrdp.2017.91","article-title":"Rabies","volume":"3","author":"Fooks","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.biologicals.2020.05.001_bib2","series-title":"Epidemiology and burden disease","author":"World Health Organization","year":"2019"},{"issue":"16","key":"10.1016\/j.biologicals.2020.05.001_bib4","first-page":"201","article-title":"WHO. Rabies vaccines: WHO position paper \u2013 april 2018","volume":"93","author":"World Health Organization","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.biologicals.2020.05.001_bib5","author":"World Organization for Animal Health"},{"key":"10.1016\/j.biologicals.2020.05.001_bib6","series-title":"The natural history of rabies","first-page":"551","article-title":"Local wound treatment and passive immunization","author":"Cabasso","year":"1991"},{"key":"10.1016\/j.biologicals.2020.05.001_bib7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biologicals.2012.07.005","article-title":"Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward","volume":"40","author":"Stokes","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2020.05.001_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jviromet.2009.01.017","article-title":"Potency evaluation of rabies vaccine for human use: the impact of the reduction in the number of animals per dilution","author":"Moura","year":"2009","journal-title":"J Virol Methods"},{"key":"10.1016\/j.biologicals.2020.05.001_bib9","series-title":"The European Pharmacopoeia","first-page":"580","article-title":"Assays depending upon quantal responses","author":"Council of Europe","year":"2008"},{"key":"10.1016\/j.biologicals.2020.05.001_bib10","series-title":"Ag\u00eancia nacional de Vigil\u00e2ncia sanit\u00e1ria \u2013 anvisa. Farmacopeia brasileira","year":"2010"},{"key":"10.1016\/j.biologicals.2020.05.001_bib11","series-title":"Ag\u00eancia nacional de Vigil\u00e2ncia sanit\u00e1ria \u2013 anvisa. Farmacopeia brasileira","year":"2004"},{"key":"10.1016\/j.biologicals.2020.05.001_bib12","series-title":"Koprowsky H. Laboratory techniques in rabies","first-page":"360","article-title":"The NIH Test for potency","author":"Wilbur","year":"1996"},{"key":"10.1016\/j.biologicals.2020.05.001_bib13","author":"Council of Europe"},{"key":"10.1016\/j.biologicals.2020.05.001_bib14","unstructured":"European Medicine Agency. EMA. Committee for Medicinal Products for Human Use (CHMP). Guideline for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs. Amsterdam, nov 2017. (EMA\/CHMP\/CVMP\/3Rs\/94436\/2014)."},{"key":"10.1016\/j.biologicals.2020.05.001_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2307\/2532051","article-title":"A concordance correlation coefficient to evaluate reproducibility","volume":"45","author":"Lin","year":"1989","journal-title":"Biometrics"},{"key":"10.1016\/j.biologicals.2020.05.001_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2307\/2532314","article-title":"Assay validation using the concordance correlation coefficient","volume":"48","author":"Lin","year":"1992","journal-title":"Biometrics"},{"key":"10.1016\/j.biologicals.2020.05.001_bib17","series-title":"Total deviation index for measuring individual agreement with applications in laboratory performance and bioequivalence","first-page":"255","author":"Lin","year":"2000"},{"key":"10.1016\/j.biologicals.2020.05.001_bib18","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1183\/09031936.01.00203101","article-title":"The repeatability of nonbronchoscopic bronchoalveolar lavage differential cell counts","volume":"18","author":"Warke","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.biologicals.2020.05.001_bib19","first-page":"162","volume":"vol. 27","author":"World Health Organization","year":"1997"},{"key":"10.1016\/j.biologicals.2020.05.001_bib20","series-title":"How should I calculate a within-subject coefficient of variation?","author":"Bland","year":"2006"},{"key":"10.1016\/j.biologicals.2020.05.001_bib21","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"327","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.biologicals.2020.05.001_bib22","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/clinchem\/43.11.2039","article-title":"Graphical interpretation of analytical data from comparison of field method with reference method by use of difference plots","volume":"43","author":"Petersen","year":"1997","journal-title":"Clin Chem"},{"key":"10.1016\/j.biologicals.2020.05.001_bib23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-1157(87)80008-2","article-title":"The effects of reductions in the numbers of animals used for the potency assay of the diphtheria and tetanus components of adsorbed vaccines by the methods of the European Pharmacopoeia","volume":"15","author":"Hendriksen","year":"1987","journal-title":"J Biol Stand"},{"key":"10.1016\/j.biologicals.2020.05.001_bib24","series-title":"A critical evaluation of animal tests in pharmacopoeial monographs","first-page":"177","article-title":"Animal welfare aspects in the quality control of immunologicals","author":"Weisser","year":"1997"},{"key":"10.1016\/j.biologicals.2020.05.001_bib25","series-title":"Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs","first-page":"109","author":"World Health Organization","year":"2007"},{"key":"10.1016\/j.biologicals.2020.05.001_bib26","series-title":"The principles of human experimental technique","author":"Russell","year":"1959"},{"key":"10.1016\/j.biologicals.2020.05.001_bib27","first-page":"53","article-title":"Reduction of numbers of animals used in the quality control of biologicals","volume":"32","author":"Hendriksen","year":"2004","journal-title":"Atla"},{"key":"10.1016\/j.biologicals.2020.05.001_bib28","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/BF01941183","article-title":"Reduction in the number of mice used for potency testing of human and animal rabies vaccines","volume":"44","author":"Bruckner","year":"1988","journal-title":"Experientia"},{"key":"10.1016\/j.biologicals.2020.05.001_bib29","first-page":"429","article-title":"Three Rs approaches in the quality control of inactivated Rabies vaccines","volume":"31","author":"Bruckner","year":"2003","journal-title":"Atla"},{"key":"10.1016\/j.biologicals.2020.05.001_bib30","series-title":"WHO. A WHO guide to good manufacturing practice (GMP) requirements","first-page":"69","article-title":"Validation of analytical assays","author":"World Health Organization","year":"1997"},{"key":"10.1016\/j.biologicals.2020.05.001_bib31","first-page":"1","article-title":"International collaborative study to assess the suitability of the candidate 7th WHO International Standard for rabies vaccine","author":"World Health Organization","year":"2018","journal-title":"Expert Comm Biol Stand"},{"key":"10.1016\/j.biologicals.2020.05.001_bib32","series-title":"The European Pharmacopoeia","first-page":"836","article-title":"Rabies vaccine for human use prepared in cell cultures","author":"Council of Europe","year":"2008"},{"key":"10.1016\/j.biologicals.2020.05.001_bib33","series-title":"The European Pharmacopoeia","first-page":"1008","article-title":"Rabies vaccine (inactivated) for veterinary use","author":"Council of Europe","year":"2017"},{"key":"10.1016\/j.biologicals.2020.05.001_bib34","first-page":"180","article-title":"The NIH Test for potency testing of vaccines","volume":"vol. 2","author":"World Health Organization","year":"2018"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105620300543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105620300543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:14:17Z","timestamp":1760922857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105620300543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":33,"alternative-id":["S1045105620300543"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2020.05.001","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potency evaluation of rabies vaccine for human use: The impact of reducing the number of animals per dilution \u2013 Part 2","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2020.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd on behalf of International Alliance for Biological Standardization.","name":"copyright","label":"Copyright"}]}}